A Study of U-500 Insulin (LY041001) in Participants With Type 2 Diabetes

Lilly

Status and phase: Terminated; Phase 1

Conditions: Diabetes Mellitus, Type 2

Treatments: Drug: U-500R

Study type: Interventional

Funder types: Industry

Identifiers

NCT02588950

B5K-EW-IBHG (Other Identifier)

16021

Details and patient eligibility

About

The purpose of this two-part study is to measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of it. In Part A, each participant will receive two treatments, a single dose and a single dose with continuous infusion of U-500R insulin, both administered just under the skin. Participants who complete Part A will continue into Part B where they will be assigned to 1 of 2 treatments with U-500R insulin, injected either twice or three times daily under the skin for 5-10 days. This study can last from 7-14 weeks including initial screening and follow up.

Enrollment: 11 patients

Sex: All

Ages: 18 to 74 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Males or females with type 2 diabetes mellitus (T2DM)
• Are current users of U-100, U-200 and/or U-300 insulin/analog as, basal, premixed and/or basal/bolus delivered with any injection device (pens and/or syringe/vial but excluding continuous subcutaneous infusion (CSII)/insulin pump use in the preceding 3 months), taking a total daily dose (TDD) of greater than or equal to (≥) 150 units (U) or at least one dose greater than (>) 100 U as part of a multiple daily injection (MDI) regimen and TDD less than or equal to (≤)3.0 units per kilogram (U/kg)
• Concomitant antihyperglycemic agent(s) (AHA) therapy may include: metformin (MET), dipeptidyl peptidase 4 inhibitors, pioglitazone (doses ≤30 milligrams per day (mg/day)), glucagon like peptide (GLP)-1 receptor agonists, sodium-glucose co-transporter-2 (SGLT2) inhibitors, except in combination with GLP-1 receptor agonists
• Participant's antihyperglycemic agent (AHA) therapy must have been stable for ≥3 months (except for weekly GLP-1 receptor agonists which must have been stable for ≥4 months)
• Have hemoglobin A1c (HbA1c) 7.5-11.5 percent (%)

Exclusion criteria

• Have type 1 diabetes mellitus (T1DM), or other types of diabetes mellitus apart from T2DM
• Have known hypersensitivities or allergies to insulin, excipients contained in insulin products, or related compounds
• Have used U-500R within 3 months prior to screening
• Have used rosiglitazone, pramlintide, once weekly or twice daily exenatide, or other injectable or oral antihyperglycemic agent(s) not listed in the inclusion criterion; or are taking oral antidiabetic medications at doses exceeding the respective product labels
• Have had a blood transfusion or severe blood loss within 3 months prior to screening or have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia which may affect reliability of HbA1c measurements

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

11 participants in 4 patient groups

Part A: U-500R Single Injection

Experimental group

Description:

Bolus of U-500R administered via single subcutaneous (SC) injection.

Treatment:

Drug: U-500R

Part A: U-500R CSII

Experimental group

Description:

Bolus of U-500R administered via continuous subcutaneous insulin infusion (CSII).

Treatment:

Drug: U-500R

Part B: U-500R TID

Experimental group

Description:

U-500R administered thrice-daily (TID) via SC injection under steady state conditions for 5 to 10 days

Treatment:

Drug: U-500R

Part B: U-500R BID

Experimental group

Description:

U-500R administered twice-daily (BID) via SC injection under steady state conditions for 5 to 10 days

Treatment:

Drug: U-500R